Landmark review calls for faster drug approval pathways in Australia
This article was originally published in SRA
Executive Summary
Experts* conducting a landmark review of Australia's healthcare products regulatory framework are calling on the government to introduce an expedited approval pathway for medicines in certain circumstances1,2.
You may also be interested in...
Australia Says Yes To Using Assessments Reports From Key International Regulators
Prescription medicines could be approved faster in Australia after the Therapeutic Goods Administration issued an initial list of overseas agencies whose assessments reports it is prepared to rely on.
Australia Plans New Approval Pathways To Foster Earlier Access To Novel Drugs
The Australian government has come up with a set of proposals for reforming the drug and medical device regulatory framework, which include speeding up access to innovative drugs through expedited and provisional approval mechanisms and greater use of assessments by overseas regulators. The changes will be phased in over a period of about three years and may include some recovery of costs from industry.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.